longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Adma Biologics

ADMA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 12.62, within the reasonable range, cheaper than 73.56% of the time in the past 1 years, and the industry ranks 31/602, the industry Median -2.32.

12.62xP/E
$9.52Stock price
$0.75Earnings per share
12.62xP/E
Stock price$9.52Earnings per share$0.75

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
16.72x
Typical range
12.24x–20.49x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.43x42.44%$4.95B
ACADUSAcadia Pharma
10.04x73.45%$3.82B
PURRUSHyperliquid Strategies
10.88x84.74%$2.79B
AUPHUSAurinia Pharma
7.03x54.40%$2.21B
ADMAUSAdma Biologics
12.62x35.42%$2.13B
LKFTUSLakefront Biotherapeutics
2.85x86.19%$1.98B
ANABUSAnaptysbio
5.90x1,051.46%$1.55B
VORUSVor BioPharma
1.74x89.77%$1.09B
MGTXUSMeiraGTx
13.44x122.03%$1.06B
ABUSUSArbutus Pharma
6.28x533.09%$961.07M
RIGLUSRigel Pharma
2.78x83.91%$894.58M
BVNRYUSBavarian Nordic A/S
3.52x--$844.51M
IRWDUSIronwood Pharma
5.33x715.55%$692.36M
AGENUSAgenus
4.17x--$382.67M
CUVLUSClinuvel Pharmaceuticals
12.72x--$291.47M
QTTBUSQ32 Bio
8.12x162.23%$274.47M
CGENUSCompugen
6.38x173.68%$224.50M
PLXUSProtalix Biotherap
11.70x400.00%$221.57M
VXRTUSVaxart
2.85x328.57%$109.93M
RLYBUSRallybio
1.94x131.45%$88.21M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.